安旭生物 (688075)
Assure Tech (Hangzhou) Co., Ltd.
K-Line Chart
No K-line data available
Company NameHangzhou Anxu Biotechnology Co., Ltd.
Listing Date2021-11-18
Issue Price78.28RMB
Registered Capital12708.280510k RMB
Legal RepresentativeLing Shisheng
Registered Address3rd Floor, Building 4, No. 1418-50 Moganshan Road, Shangcheng Science & Technology Industrial Base, Hangzhou City, Zhejiang Province
IndustryMedical Devices
Main BusinessFocuses on the R&D, production, and sales of POCT reagents and instruments
Company ProfileHangzhou Anxu Biotechnology Co., Ltd. was founded in 2008. Located in the beautiful city of Hangzhou, the company is a high-tech biomedical enterprise integrating R&D, production, and sales of in vitro diagnostic reagents, POCT instruments, and biological raw materials.
The company possesses a 20,000-square-meter production and R&D base and has established an internationally advanced production line for colloidal gold rapid diagnostic reagents, with an annual production capacity exceeding hundreds of millions of test units. It currently has over 100 R&D personnel, more than 80% of whom hold bachelor's degrees. The company has established extensive project cooperation relationships with domestic and international research institutions and maintains a leading domestic position in areas such as rapid diagnostic reagent platforms, molecular rapid diagnostic platforms, immune antibody development and preparation, small molecule antigen synthesis, and genetic engineering.
The company is dedicated to the R&D and production of in vitro diagnostic reagents and related POCT instruments, including colloidal gold rapid test reagents, chemiluminescence immunoassay quantitative reagents, and bioactive raw materials. It has successfully developed over 100 products across nine major series, including pregnancy, drugs of abuse, infectious diseases, tumor markers, cardiac markers, food safety, biochemistry, allergens, and integrated instrument-reagent systems.
Stock Details
1. Key Indicators
- Total Shares(W): 734059.07
- Circulating A-Shares(W): 734059.07
- Earnings Per Share(RMB): 1.23
- Net Assets Per Share(RMB): 5.67
- Operating Revenue(W RMB): 1345261.60
- Total Profit(W RMB): 1345261.60
- **Net Profit Attributable to Parent(W RMB) **: 1345261.60
- Net Profit Growth Rate(%): -55.89
- Weighted Return on Equity(%): 4.6500
- Operating Cash Flow Per Share(RMB): 1.23
- Undistributed Profit Per Share(RMB): 1.23
- Capital Reserve Per Share(RMB): 1.23
2. Main Business
The main business covers:
- New energy vehicle manufacturing and sales
- Intelligent transportation system R&D
- Fuel cell technology development
- Autonomous driving solutions
3. Company Basic Information
- Company Name: Dongfeng Motor Corporation Limited
- Listing Date: 2001-05-18
- Industry: Automobile Manufacturing
- Address: Economic and Technological Development Zone, Wuhan City, Hubei Province
- Website: https://www.dongfeng.com.cn/
- Company Profile: The company was established with Beijing Capital Venture Group as the main sponsor....
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | China Securities Finance Co., Ltd. | National Team | 5,000 | 10.2 |
| 2 | ChinaAMC | Public Fund | 3,200 | 6.5 |
| 3 | Hillhouse Capital | Private Equity Fund | 2,800 | 5.7 |
| 4 | National Social Security Fund | National Team | 2,500 | 5.1 |
| 5 | E Fund | Public Fund | 2,000 | 4.1 |
| 6 | HTFF | Public Fund | 1,800 | 3.7 |
| 7 | CITIC Securities | Securities Company | 1,500 | 3.1 |
| 8 | Guotai Junan | Securities Company | 1,200 | 2.4 |
| 9 | China Merchants Bank | Bank | 1,000 | 2.0 |
| 10 | ICBC Credit Suisse | Public Fund | 900 | 1.8 |
5. Concept Sectors
- Carbon Neutrality
- Intelligent Transportation
- Fuel Cell
- Autonomous Driving
- New Energy Vehicles
- Hydrogen Energy
- Huawei Auto
- Vehicle Networking
Remarks
- Data update date: 2025-11-02
- Data source: Public Market Information